[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 257
Citations 0
Comment & Response
July 2016

Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies—Reply

Author Affiliations
  • 1Neuroimmunology Program, Institut d’Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain
  • 2Service of Neurology, Hospital Clinic, Barcelona, Spain
  • 3Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
  • 4Department of Neurology, University of Pennsylvania, Philadelphia
JAMA Neurol. 2016;73(7):891. doi:10.1001/jamaneurol.2016.1164

In Reply We thank Gallerini and colleagues for bringing to our attention a new case of opsoclonus associated with a gastric adenocarcinoma. The patient confirms the tight association of older age with a paraneoplastic etiology of the opsoclonus.1

As the authors mention, gastric cancer is rarely seen in patients with paraneoplastic opsoclonus who usually have breast or small-cell lung cancer.2 In addition to the previously reported cases reviewed by Gallerini and colleagues, we would include another case who also presented with Ma2 antibodies.3 Last, patients with opsoclonus and a high suspicion of an underlying tumor should be evaluated according to proposed guidelines to detect the occult neoplasm in paraneoplastic neurological syndromes.4

First Page Preview View Large
First page PDF preview
First page PDF preview
×